Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 16,133 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorders Clear all

Conditions: Rheumatoid Arthritis
Interventions: tocilizumab SC, tocilizumab IV, placebo to tocilizumab SC, placebo to tocilizumab IV, Disease-modifying antirheumatic drugs (DMARDs); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 54
States / cities: Huntsville, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 48 more

Conditions: Mucopolysaccharidosis IV Type A, Morquio A Syndrome, MPS IVA
Interventions: Imaging, gait analysis, growth, joint test, hearing test, questionnaire, etc.; Diagnostic Test
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Breast Cancer, Gynecologic Cancer
Interventions: prasterone, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 280
States / cities: Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 185 more

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, BRCA-Associated Malignant Neoplasm, BRCA Hereditary Ovarian Carcinoma, Metastatic BRCA Hereditary Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Primary Peritoneal Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Unresectable Breast Carcinoma, Unresectable Fallopian Tube Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Ovarian Carcinoma, Unresectable Pancreatic Carcinoma, Unresectable Primary Peritoneal Carcinoma
Interventions: Dostarlimab, Niraparib, Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging; Biological · Drug · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Estrogen Receptor Positive Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer
Interventions: [18F]FES; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Melanoma Recurrent, Malignant Melanoma, Melanoma
Interventions: Vigil, Pembrolizumab; Biological · Drug
Lead sponsor: Gradalis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 3
States / cities: Abilene, Texas • Dallas, Texas • Spokane, Washington

Conditions: Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions: Autologous cultured dermal and epidermal cells; Biological
Lead sponsor: Aderans Research Institute; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 4
States / cities: Birmingham, Alabama • Tucson, Arizona • Pinellas Park, Florida + 1 more

Conditions: Progressive Pulmonary Fibrosis
Interventions: BMS-986278, BMS-986278 Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 21 Years and older
Enrollment: 1,057 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 81
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 70 more

Conditions: Asthma, Allergies
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Atopic Dermatitis
Interventions: Barzolvolimab, Matching placebo; Biological · Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 33
States / cities: Birmingham, Alabama • Beverly Hills, California • Burbank, California + 28 more

Conditions: Lung Cancer, Ovarian Cancer, Breast Cancer, Hodgkin's Disease, Neuroblastoma
Interventions: Symptom Assessment Scale; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Letrozole, Placebo; Drug
Lead sponsor: Carol Fabian, MD; Other
Eligibility: 30 Years to 69 Years · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2018
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Neoplasms, Breast
Interventions: Lapatinib, Trastuzumab; Drug · Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 87
States / cities: Phoenix, Arizona • Sedona, Arizona • Highland, California + 79 more

Conditions: METASTATIC BREAST CANCER
Interventions: Positron emission tomography (PET/CT) imaging, radiotracer [18F]ISO-1; Device
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Metastatic Breast Cancer
Interventions: Palbociclib, Fulvestrant, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 521 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 134
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 90 more

Conditions: Psoriatic Arthritis
Interventions: Open label H.P. Acthar Gel; Drug
Lead sponsor: Fiechtner, Justus J., M.D., P.C.; Individual
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Lansing, Michigan

Conditions: Breast Cancer, Precancerous Condition
Interventions: omega-3 fatty acid, placebo; Dietary Supplement · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 21 Years to 120 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: Actinic Keratosis
Interventions: LEO 43204 Formulation 1, LEO 43204 Formulation 2, LEO 43204 Formulation 1 Dose X, LEO 43204 Formulation 1 Dose Y, LEO 43204 Formulation 2 Dose XX, LEO 43204 Formulation 2 Dose YY, Placebo Formulation 1, Placebo Formulation 2; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 13
States / cities: Phoenix, Arizona • Lomita, California • San Diego, California + 9 more

Conditions: Psoriasis
Interventions: Rimegepant, Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: New York, New York

Conditions: Stenosis, Histiocytoma
Interventions: Not listed
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 0 Years to 90 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2000
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Arthritis, Rheumatoid Arthritis
Interventions: CDP6038, Placebo IV, Placebo SC, CDP 6038 SC, Methotrexate; Biological · Other · Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Duncansville, Pennsylvania • Dallas, Texas • San Antonio, Texas

Conditions: Diabetic Ulcers on Both Feet, Amputation; Traumatic, Limb, Sexual Dysfunction, Diabetic Foot Ulcer Ischemic
Interventions: Diabetes education; Behavioral
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Triple Negative Breast Cancer
Interventions: gemcitabine plus carboplatin plus BSI-201; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 2
States / cities: Stanford, California • Philadelphia, Pennsylvania

Search by objective public record fields.

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis

Non-invasive Functional Assessment and Pathogenesis of Morquio A

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

[18F]FES PET/CT in Endocrine Refractory Breast Cancer

Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004541)

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

Cohort Study of the Patterns of Microvesicles in the Serum of Participants With Atopic and Non-atopic Asthma

A Study of Barzolvolimab in Patients With Atopic Dermatitis

Prevalence+Significance of Paraneoplastic Autoantibodies in Many Cancers

Study of Breast Cancer Prevention by Letrozole in High Risk Women

Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer

Imaging of in Vivo Sigma-2 Receptor Expression With 18F-ISO-1 Positron Emission Tomography in Metastatic Breast Cancer

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis

Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia

A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis

Rimegepant in Moderate Plaque-type Psoriasis

Genetic Study of Patients and Families With Diaphyseal Medullary Stenosis With Malignant Fibrous Histiocytoma of the Bone

An Observational Pilot Study to Test a Smartwatch-based EMA Method During Exercise With Breast Cancer Survivors

To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate

The Impact of Sexual Health and Amputation Focused Education on Regulation of Glucose and Amputation Prevention

A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer